Wizmedi Bio signs Memorandum of Understanding with China's Wuchan Zhongda Group

ⓒWizmedi Bio Co., Ltd.

Wizmedi Bio Co., Ltd. officially announced that it had entered into a Memorandum of Understanding (MoU) with Wuchan Zhongda Life on the Chinese license and distribution of BoNT-A6, a patented novel botulinum toxin subtype, developed in the United States.

Wuchan Zhongda Life is a first-tier subsidiary of the consumer goods division of Wuchan Zhongda Group, a Chinese state-owned enterprise ranked 138th on the Fortune Global 2023 list. In the post-reform evaluation of mixed ownership enterprises, Wuchan Zhongda Life has been recognized as a model company (Grade A).

In March 2024, Wizmedi Bio signed an exclusive worldwide license agreement with the Wisconsin Alumni Research Foundation (WARF), established by the University of Wisconsin, for the patent and technical licensing of BoNT-A6.

In addition, the company has signed consulting agreements with two internationally renowned botulinum toxin experts, Dr. Eric A. Johnson, retired professor of bacteriology at the University of Wisconsin-Madison in the US, and Professor Dirk Dressler, head of the Movement Disorders Section at Hannover Medical School in Germany.

Yong-Hun Choi, CEO of Wizmedi Bio, stated, "Through this agreement with Wuchan Zhongda Group, we will aggressively target China, the second largest botulinum toxin market in the world.”